Upgrades - Baird upgraded Henry Schein (HSIC) to Outperform from Neutral with a price target of $100, up from $78, citing an upside bias across its dental names [2] - UBS upgraded BlackRock (BLK) to Buy from Neutral with a price target of $1,280, supported by strong Q4 results and positive commentary at the UBS Financials conference [2] - Lake Street upgraded Tandem Diabetes (TNDM) to Buy from Hold with a price target of $50, up from $14, believing the transition to a pharmacy model will lead to predictable growth and improved margins [3] - Aletheia upgraded Nvidia (NVDA) to Buy from Hold with a price target of $250, viewing the stock as "too cheap to ignore" ahead of Nvidia's Q4 report [3] - Wells Fargo upgraded Alphabet (GOOGL) to Overweight from Equal Weight with a price target of $387, up from $354, highlighting its leadership in key AI traits [4] Downgrades - Jefferies downgraded Workday (WDAY) to Hold from Buy with a price target of $150, down from $325, noting that apps software names have been hit harder than overall software [5] - BofA downgraded General Mills (GIS) to Neutral from Buy with a price target of $48, down from $55, following the CAGNY conference and a stale Buy thesis [5] - Baird downgraded Arcellx (ACLX) to Neutral from Outperform with a price target of $115, down from $106, after Gilead Sciences announced an acquisition agreement [5] - JPMorgan downgraded VF Corp. (VFC) to Underweight from Neutral with a price target of $18, down from $19, after reducing earnings estimates [5] - Jefferies downgraded Deere (DE) to Underperform from Hold with a price target of $550, up from $475, citing the need for improved U.S. farmer incomes for recovery [5]

The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need to know, as compiled by The Fly.Top 5 Upgrades: Barclays upgraded Etsy (ETSY) to Overweight from Equal Weight with a price target of $72, up from $62. The firm sees the company's sale of Depop and its core business hovering around flattish after years of declines as a "tipping point" for Etsy, the firm tells investors in a research note. Argus upgraded Deck ...

Surpassed $1 billion in annual sales in 2025, driven by record fourth-quarter pump shipments and double-digit growth in both U.S. and international markets. Management is fundamentally reshaping the business model by transitioning to a 'pay-as-you-go' (PayGo) reimbursement structure in the pharmacy channel to reduce patient out-of-pocket barriers. The shift to pharmacy is expected to double the lifetime revenue per patient while streamlining the prescription process for healthcare providers and improv ...

Company Overview - Senseonics has launched the full U.S. availability of its Eversense 365 Continuous Glucose Monitoring (CGM) system, integrated with Sequel Med Tech's twiist Automated Insulin Delivery (AID) system for type 1 diabetes patients [1][7] - The Eversense 365 CGM system offers a wear time of up to 365 days, significantly longer than the maximum of 15 days for other approved CGM devices from competitors like DexCom and Abbott [2][7] Financial Performance - Senseonics reported total revenues of $21 million, which is considerably lower than competitors DexCom and Abbott, who recorded $5.6 billion and $3.4 billion in sales related to CGM devices, respectively, in the first nine months of 2025 [4] - The company expects total revenues for 2026 to be in the range of $58-$62 million, representing an increase of 65% to 76% over 2025 revenue [12] Market Dynamics - The total CGM devices market size was valued at $13.66 billion in 2024 and is projected to grow at a CAGR of 15.4%, reaching $49.87 billion by 2033, driven by the rising prevalence of diabetes and technological advancements [10] - The integration of Eversense 365 with the twiist AID system is expected to enhance customer adoption and drive sales growth in 2026 [4][8] Recent Developments - Senseonics received CE Mark approval for the Eversense 365 CGM system and plans to launch it in Germany, Italy, Spain, and Sweden in the coming months [11] - The company reported a 71% year-over-year increase in total revenues for the fourth quarter of 2025, with new patients in the U.S. increasing by 103% from the previous year [12]

Internationally, Q4 sales grew 17% year over year to $80 million on 11,000 pump shipments, aided by growth in both pump and supply shipments. Vosseller noted favorable foreign exchange, offset by $4 million tied to the company’s transition to direct operations that primarily affected pump sales. For 2025, total distributor destocking and inventory buyback impact was about $7 million, below the company’s earlier estimate of $10 million due to a partial timing shift into the first quarter of 2026.In the fourt ...

Core Viewpoint - Rosen Law Firm is investigating potential securities claims on behalf of shareholders of Tandem Diabetes Care, Inc. due to allegations of materially misleading business information issued by the company [1]. Group 1: Company Information - Tandem Diabetes Care, Inc. is facing scrutiny after a press release on August 7, 2025, announced a voluntary medical device correction for select t:slim X2 insulin pumps, which could lead to a discontinuation of insulin delivery due to a speaker-related issue [3]. - Following the announcement, Tandem Diabetes' stock experienced a significant decline of 19.9% on the same day [3]. Group 2: Legal Actions - Investors who purchased Tandem Diabetes securities may be eligible for compensation through a class action lawsuit being prepared by Rosen Law Firm, which operates on a contingency fee basis [2]. - The firm emphasizes the importance of selecting qualified legal counsel with a proven track record in securities class actions, highlighting its own success in recovering substantial amounts for investors [4]. Group 3: Firm's Credentials - Rosen Law Firm has achieved notable recognition, including the largest securities class action settlement against a Chinese company and being ranked No. 1 for securities class action settlements in 2017 [4]. - The firm has consistently ranked in the top 4 for securities class action settlements since 2013 and has recovered hundreds of millions of dollars for investors, including over $438 million in 2019 alone [4].

Core Viewpoint - Hologic reported quarterly earnings of $1.04 per share, missing the Zacks Consensus Estimate of $1.09 per share, representing an earnings surprise of -4.46% [1]. Financial Performance - The company posted revenues of $1.05 billion for the quarter ended December 2025, which was below the Zacks Consensus Estimate by 2.14%, compared to $1.02 billion in the same quarter last year [2]. - Over the last four quarters, Hologic has surpassed consensus EPS estimates three times and topped consensus revenue estimates three times [2]. Stock Performance - Hologic shares have increased by approximately 0.8% since the beginning of the year, while the S&P 500 has gained 1.9% [3]. - The current Zacks Rank for Hologic is 3 (Hold), indicating that the shares are expected to perform in line with the market in the near future [6]. Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is $1.09 on revenues of $1.05 billion, and for the current fiscal year, it is $4.51 on revenues of $4.28 billion [7]. - The trend of earnings estimate revisions for Hologic was mixed ahead of the earnings release, which could change following the recent report [6]. Industry Context - The Medical - Instruments industry, to which Hologic belongs, is currently in the top 38% of over 250 Zacks industries, suggesting a favorable outlook compared to the bottom 50% [8].

Market Overview - U.S. equity markets in Q4 2025 were influenced by optimism regarding potential monetary easing and caution related to economic growth and valuations [1] - Early gains were attributed to strong AI-related earnings and a rate cut by the US Federal Reserve in October, but sentiment cooled later due to mixed signals from the Fed [1] - Large caps rose 17.4% for the year and 2.4% in the quarter, while small caps gained 12.8% for the year and 2.2% in the quarter [1] - Value stocks outperformed growth stocks, returning 3.3% versus 1.2% for the quarter [1] Fund Performance - Meridian Growth Fund delivered a return of -0.39% (net) in Q4 2025, underperforming the Russell 2500 Growth Index's return of 0.33% [1] - The firm is monitoring factors that may impact market returns, including changes in monetary policy and the sustainability of AI investments due to high valuations among hyperscalers [1] Company Spotlight: Tandem Diabetes Care, Inc. - Tandem Diabetes Care, Inc. (NASDAQ:TNDM) was highlighted as a leading contributor in the Meridian Growth Fund's Q4 2025 investor letter [2] - The company specializes in technology solutions for diabetes management, particularly advanced insulin delivery systems [3] - Tandem's stock traded between $9.98 and $37.93 over the past 52 weeks, closing at $20.20 on January 26, 2026, with a market capitalization of $1.37 billion [2] - The stock experienced a one-month return of -10.26% but gained 33.77% over the last three months [2] - The company is well-positioned to capture market share in a growing addressable market, as many Type 1 diabetes patients still manage insulin manually [3]

Core Viewpoint - Rosen Law Firm is investigating potential securities claims on behalf of shareholders of Tandem Diabetes Care, Inc. due to allegations of materially misleading business information issued by the company [1]. Group 1: Investigation and Legal Action - Shareholders who purchased Tandem Diabetes securities may be entitled to compensation through a class action lawsuit without any out-of-pocket fees [2]. - The Rosen Law Firm is preparing a class action to seek recovery of investor losses related to the allegations against Tandem Diabetes [2]. Group 2: Company Incident - On August 7, 2025, Tandem Diabetes issued a press release regarding a voluntary medical device correction for select t:slim X2 insulin pumps, addressing a potential speaker-related issue that could lead to insulin delivery discontinuation [3]. - Following this announcement, Tandem Diabetes' stock experienced a significant decline of 19.9% on the same day [3]. Group 3: Rosen Law Firm's Credentials - The Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions [4]. - The firm has achieved notable settlements, including the largest securities class action settlement against a Chinese company and has consistently ranked highly in securities class action settlements since 2013 [4]. - In 2019, the firm secured over $438 million for investors, showcasing its capability in recovering significant amounts for its clients [4].

Core Viewpoint - Rosen Law Firm is investigating potential securities claims on behalf of shareholders of Tandem Diabetes Care, Inc. due to allegations of materially misleading business information issued by the company [1]. Group 1: Investigation Details - The investigation is focused on claims that Tandem Diabetes Care may have misled investors regarding its business practices [1]. - A class action is being prepared by Rosen Law Firm to seek recovery of investor losses, allowing affected shareholders to join without upfront costs [2]. Group 2: Incident Overview - On August 7, 2025, Tandem Diabetes issued a press release regarding a voluntary medical device correction for select t:slim X2 insulin pumps, addressing a potential speaker-related issue that could lead to insulin delivery discontinuation [3]. - Following this announcement, Tandem Diabetes' stock experienced a significant decline of 19.9% on the same day [3]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a proven track record in securities class actions, highlighting its own success in this area [4]. - The firm has achieved notable settlements, including the largest securities class action settlement against a Chinese company, and has consistently ranked highly in securities class action settlements since 2013 [4].